NASDAQ:CNTX Context Therapeutics (CNTX) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free CNTX Stock Alerts $1.41 +0.03 (+2.18%) (As of 04/26/2024 08:52 PM ET) Add Compare Share Share Today's Range$1.37▼$1.4550-Day Range$1.04▼$1.5252-Week Range$0.47▼$1.69Volume20,100 shsAverage Volume51,269 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Context Therapeutics alerts: Email Address Context Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside183.7% Upside$4.00 Price TargetShort InterestHealthy0.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.38) to ($0.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.32 out of 5 stars 3.5 Analyst's Opinion Consensus RatingContext Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageContext Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.29% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Context Therapeutics has recently increased by 260.71%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldContext Therapeutics does not currently pay a dividend.Dividend GrowthContext Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CNTX. Previous Next 0.8 News and Social Media Coverage News SentimentContext Therapeutics has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Context Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for CNTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Context Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.66% of the stock of Context Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 14.03% of the stock of Context Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Context Therapeutics are expected to grow in the coming year, from ($1.38) to ($0.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Context Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Context Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContext Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About Context Therapeutics Stock (NASDAQ:CNTX)Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Read More CNTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNTX Stock News HeadlinesApril 26, 2024 | americanbankingnews.comContext Therapeutics (NASDAQ:CNTX) vs. CytomX Therapeutics (NASDAQ:CTMX) Head-To-Head ComparisonApril 20, 2024 | americanbankingnews.comContext Therapeutics (NASDAQ:CNTX) Shares Down 6.4% April 29, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 3, 2024 | msn.comContext Therapeutics Takes Bold Step with IND Submission for Groundbreaking Cancer TherapyApril 2, 2024 | cnn.comContext Therapeutics, Inc.April 1, 2024 | markets.businessinsider.comContext Therapeutics Submits IND For CTIM-76April 1, 2024 | globenewswire.comContext Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive CancersMarch 22, 2024 | markets.businessinsider.comBuy Rating Justified by Advances in T Cell Engagers and Context Therapeutics’ Strategic Drug PositioningApril 29, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.March 21, 2024 | investorplace.comCNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023March 21, 2024 | finanznachrichten.deContext Therapeutics Inc.: Context Therapeutics Reports Full Year 2023 Operating and Financial ResultsMarch 21, 2024 | globenewswire.comContext Therapeutics Reports Full Year 2023 Operating and Financial ResultsDecember 27, 2023 | benzinga.comContext Therapeutics Stock (NASDAQ:CNTX), Short Interest ReportDecember 27, 2023 | benzinga.comContext Therapeutics Stock (NASDAQ:CNTX) Dividends: History, Yield and DatesNovember 28, 2023 | msn.comContext Therapeutics (CNTX) Price Target Increased by 21.31% to 3.77November 10, 2023 | finanznachrichten.deContext Therapeutics Inc.: Context Therapeutics Reports Third Quarter 2023 Operating and Financial ResultsNovember 10, 2023 | proactiveinvestors.comContext Therapeutics prepares for CTIM-76 filing, ends 3Q with enough cash to last through late 2024November 9, 2023 | msn.comContext Therapeutics GAAP EPS of -$0.37 misses by $0.06November 9, 2023 | finance.yahoo.comContext Therapeutics Reports Third Quarter 2023 Operating and Financial ResultsNovember 2, 2023 | msn.comHC Wainwright & Co. Upgrades Context Therapeutics (CNTX)November 1, 2023 | benzinga.comContext Therapeutics Stock (NASDAQ:CNTX), Analyst Ratings, Price Targets, PredictionsOctober 31, 2023 | proactiveinvestors.comContext Therapeutics reveals ‘encouraging’ preclinical data for CTIM-76 tumor treatmentOctober 31, 2023 | finance.yahoo.comContext Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76October 8, 2023 | finance.yahoo.comContext Therapeutics Inc. (CNTX)October 5, 2023 | msn.comContext Therapeutics (CNTX) Price Target Increased by 45.24% to 3.11September 28, 2023 | markets.businessinsider.comContext Therapeutics’ Promising CLDN6 Targeting Asset CTIM-76 and Potential Market Valuation Opportunities: An Analyst’s Buy Rating PerspectiveSeptember 27, 2023 | proactiveinvestors.comContext Therapeutics says CTIM-76 abstract accepted for presentation at SITC annual meetingSee More Headlines Receive CNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/29/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CNTX CUSIPN/A CIK1842952 Webwww.contexttherapeutics.com Phone267-225-7416FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+183.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-115.50% Return on Assets-97.04% Debt Debt-to-Equity RatioN/A Current Ratio3.83 Quick Ratio3.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book1.91Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta2.17 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Martin A. Lehr (Age 40)Co-Founder, President, CEO & Director Comp: $725.25kMs. Jennifer Minai-Azary (Age 46)CFO & Treasurer Comp: $533.65kMr. Alex C. Levit Esq. (Age 45)Chief Legal Officer & Corporate Secretary Comp: $512.1kMr. Christopher Beck M.B.A.Senior Vice President of OperationsKey CompetitorsGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPPharvarisNASDAQ:PHVSView All CompetitorsInstitutional OwnershipOpaleye Management Inc.Bought 975,000 shares on 2/15/2024Ownership: 6.107%View All Institutional Transactions CNTX Stock Analysis - Frequently Asked Questions Should I buy or sell Context Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Context Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CNTX shares. View CNTX analyst ratings or view top-rated stocks. What is Context Therapeutics' stock price target for 2024? 2 brokerages have issued twelve-month target prices for Context Therapeutics' stock. Their CNTX share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 183.7% from the stock's current price. View analysts price targets for CNTX or view top-rated stocks among Wall Street analysts. How have CNTX shares performed in 2024? Context Therapeutics' stock was trading at $1.13 on January 1st, 2024. Since then, CNTX stock has increased by 24.8% and is now trading at $1.4101. View the best growth stocks for 2024 here. Are investors shorting Context Therapeutics? Context Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 40,400 shares, an increase of 260.7% from the March 31st total of 11,200 shares. Based on an average daily trading volume, of 55,500 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.3% of the shares of the company are sold short. View Context Therapeutics' Short Interest. When is Context Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CNTX earnings forecast. How were Context Therapeutics' earnings last quarter? Context Therapeutics Inc. (NASDAQ:CNTX) released its earnings results on Thursday, March, 21st. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.07. When did Context Therapeutics IPO? Context Therapeutics (CNTX) raised $25 million in an initial public offering (IPO) on Wednesday, October 20th 2021. The company issued 5,000,000 shares at $5.00 per share. How do I buy shares of Context Therapeutics? Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CNTX) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryHas Jeff Bezos Found the Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
